Atacand vs. Cozaar
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Labeling for AstraZeneca's angiotensin II receptor blocker Atacand (candesartan) may report data showing superior reduction in diastolic blood pressure over Merck's ARB Cozaar (losartan), FDA's Cardiovascular & Renal Drugs Advisory Committee concludes July 18. AstraZeneca's two CLAIM studies showed 1.5 and 2.2 mm Hg greater reductions in DBP for once-daily Atacand vs. once-daily Cozaa